Compare · ADMS vs UROV
ADMS vs UROV
Side-by-side comparison of Adamas Pharmaceuticals, Inc. (ADMS) and Urovant Sciences Ltd. (UROV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADMS and UROV operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- ADMS carries a market cap of $373.6M.
- ADMS has more recent analyst coverage (5 ratings vs 0 for UROV).
- Company
- Adamas Pharmaceuticals, Inc.
- Urovant Sciences Ltd.
- Price
- $8.21+0.61%
- -
- Market cap
- $373.6M
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2018
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 0
Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Latest ADMS
- SEC Form SC 13G/A filed by Adamas Pharmaceuticals, Inc. (Amendment)
- SEC Form 15-12B filed by Adamas Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Adamas Pharmaceuticals, Inc.
- SEC Form 4: Bigham Michael closing all direct ownership in the company
- SEC Form 4: Mahoney David L closing all direct ownership in the company
- SEC Form 4: Prentiss Christopher B was granted 18,750 shares, closing all direct ownership in the company
- SEC Form 4: Mcfarlane Neil F. was granted 75,000 shares, closing all direct ownership in the company
- SEC Form 4: Ericson William W. closing all direct ownership in the company
- SEC Form 4: Shreedhar Vijay was granted 18,750 shares, closing all direct ownership in the company
- SEC Form 4: Papapetropoulos Spyridon closing all direct ownership in the company
Latest UROV
- Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
- Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg
- Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
- SEC Form 15-12B filed by Urovant Sciences Ltd.
- SEC Form EFFECT filed by Urovant Sciences Ltd.
- SEC Form 4: E. Bryan Smith disposed to the issuer $0 worth of Common Shares (124,447 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Sef Kurstjens disposed to the issuer $0 worth of Common Shares (21,480 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: M. James Hindman disposed to the issuer $0 worth of Common Shares (9,000 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Cornelia Haag-Molkenteller disposed to the issuer $0 worth of Common Shares (141,348 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Ajay Bansal disposed to the issuer $0 worth of Common Shares (140,098 units at $0.00), decreasing direct ownership by 100% to 0 units